Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.89 USD | +1.38% | -5.29% | -14.82% |
30/04 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer | CI |
08/03 | Akero Therapeutics Raises $367 Million From Share Offering | MT |
Evolution of the average Target Price on Akero Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Akero Therapeutics, Inc.
HC Wainwright | |
UBS | |
Cantor Fitzgerald | |
Morgan Stanley | |
Evercore ISI | |
Canaccord Genuity | |
Chardan | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- AKRO Stock
- Consensus Akero Therapeutics, Inc.